SF3B1 and myelodysplastic syndrome: In addition, there may also be relevant evidence that can be extracted based on the pathways associated with splicing features, suggesting prognostic information for SF3B1 mutant MDS patients that can be further developed as biomarkers for risk stratification (13) (Supplementary Figure 2).